Certara introduced TFL Studio, a cloud‑native module of its Phoenix Cloud solution, on Nov 4 2025. The tool enables pharmacokinetic and pharmacodynamic scientists to generate tables, figures, and listings (TFLs) more efficiently and with greater visual consistency.
TFL Studio offers a no‑code environment that can produce high‑quality TFLs up to 50 % faster than traditional workflows. The module is tightly integrated with Integral, Certara’s data repository, providing a single source of truth for PK/PD data, models, and visualizations and streamlining the entire data‑to‑report pipeline.
The launch is part of Certara’s broader strategy to expand its cloud‑native offerings and strengthen its Phoenix Cloud platform. The company’s 2,400+ biopharmaceutical customers could benefit from the new tool’s speed and consistency, potentially increasing recurring revenue from the cloud platform. Management highlighted that the launch aligns with industry trends toward cloud‑based solutions for drug discovery and development.
CEO William F. Feehery said the introduction of TFL Studio marks a pivotal moment in Certara’s mission to bring advanced, cloud‑native solutions to drug discovery and development. He added that a complementary AI PK Reports module, leveraging the CoAuthor generative‑AI engine, will be released later this quarter to further accelerate report drafting.
The launch follows Certara’s recent AI‑powered initiatives, including the Certara IQ platform launched on Oct 30 2025, and the CoAuthor regulatory writing software released in June 2024. These developments underscore the company’s commitment to integrating AI and predictive modeling across its product portfolio.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.